No Detail Found!

Genotype Specific Svr and Nsvr Response of Hepatitis C to the Combined Interferon and Ribavirin Therapy.

Author(s)
Muhammad Saqib Shahzad Faculty of Life Sciences, University of the Central Punjab, Johar Town, Lahore 54000, Pakistan
Amina Arif Faculty of Life Sciences, University of the Central Punjab, Johar Town, Lahore 54000, Pakistan
Saeeda Kalsoom Institute of Molecular Biology and Biotechnology, University of Lahore, Lahore, Pakistan
Javed Iqbal Department of Dentistry, Punjab Medical College, Faisalabad, Pakistan
Shahnam Shafique Institute of Molecular Biology and Biotechnology, University of Lahore, Lahore, Pakistan
Muhammad Shahid Nadeem Department of Biochemistry, King Abdulaziz University, Jeddah 21589, Saudi Arabia
Rafique Ahmed Department of Surgery, Government Kot Khawaja Saeed Teaching Hospital, Lahore 54000, Pakistan
Abstract
The objective of present study was to evaluate the therapeutic effectiveness of combined ribavirin (RBV) and interferon (IFN) therapy in hepatitis C virus (HCV) patients. Overall, 590 HCV patients were evaluated pre and post combined drug therapy during the period 2015-2017. Distribution of HCV genotypes, age groups, viral load and alanine aminotransferase (ALT) values were recorded and analyzed for rapid virologic response (RVR), non-rapid virologic response (NRVR), sustained virologic response (SVR) and non-sustained virologic response (NSVR). Among the evaluated patients RVR was found among 81.5% and NRVR among 18.5%. Out of RVR patients, SVR was found in majority (80.2%). However, among NRVR equal percentage of SVR and NSVR was found. An inverse association of SVR was found against the patient age and viral load in the plasma. The plasma values of ALT have shown no specific relation with SVR and NSVR. Genotype 3a was the most prevalent (69.7%) followed by 3b (13.6%), mixed genotypes (10.5%), 1b (3.2%), 1a (3.1%) among the investigated patients. We found highest SVR against genotype 3a (79.4%), followed by 3b (56%), 1a (33%), 1b (37.3%), 3a+3b mixed infection (29%), and 1a+1b mixed infection 24.9%. In summary, we found a genotype specific response of drug therapy against HCV. Our findings can guide the local clinicians to inform the patients about the possible effectiveness of drug therapy and to manage the disease with more efficient plan.
Publication Details
Page(s) 533-539
Published Journal: Pakistan Journal of Zoology, Volume: 51, Issue: 2, Year: 2019

Request the full text from PASTIC

References
Alexopoulou , A.,Karayiannis , P., 2015.Interferonbased combination treatment for chronic hepatitis C in the era of direct acting antivirals,Annls 28 55 -
Asahina , Y.,Tsuchiya , K.,Tamaki , N.,Hirayama , I.,Tanaka , T.,Sato , M.,Yasui , Y.,Hosokawa , T.,Ueda , K.,Kuzuya , T., 2010.Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection,Hepatology 52 518 -527
Attaullah , S.,Khan , S.,Ali , I., 2011.Hepatitis C virus genotypes in Pakistan: A systemic review,Virol. J. 8 8 -
Aziz , H.,AminAthar,M. , Murtaza,S. , Irfan,J. , Waheed,Y. and Bilal,I., 2011.Predictors of response to antiviral therapy in patients with chronic hepatitis C from Pakistani population. Chinese med, 124 1333 -
Borroni , G.,Andreoletti , M.,Casiraghi , M.,Ceriani , R.,Guerzoni , P.,Omazzi , B.,TERRENI,Salerno , F., 2008.Effectiveness of pegylated interferon/ ribavirin combination in 'real world'patients with chronic hepatitis C virus infection,Aliment. Pharmacol. Therapeut. 03657 2036 -797
Brown, 2005.Hepatitis C and liver transplantation,Nature 436 973 -
Chen , A.Y.,Zeremski , M.,Chauhan , R.,Jacobson , I.M.,Talal , A.H.,Michalak , T.I., 2013.Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy,PLoS One 8 -
Chou , R.,Hartung , D.,Rahman , B.,Wasson , N.,Cottrell , E.,Fu , R.,-,-EF, 2018.Treatment for hepatitis C virus infection in adults. Comparative effectiveness review No. 76. Agency for Healthcare Research and Quality,on 09 September 12 -
de Mattos , A.A. and de Mattos, Â. Z., 2010.Treatment of HCV infection in patients with cirrhosis,Annls. Hepatol. 9 80 -83
Dogan,Akin , M.S.,Yalaki , S., 2013.Sustained virological response based on the week 4 response in hepatitis C virus genotype 1 patients treated with peginterferons α-2a and α-2b, plus ribavirin,Eur. J. Gastroenterol. Hepatol. 25 1317 -1320
Dou , Z.,Chen,Xu , J.,Y. , Jiao,J.H. , Durako,S. , Zhao,Y. , Zhao,D. , Fang,H.,Zhang, 2002.Changing baseline characteristics among patients in the China national free antiretroviral treatment program,, 39 56 -64
Duffy , S.,Shackelton , L.A.,Holmes , E.C., 2008.Rates of evolutionary change in viruses: Patterns and determinants,Nat. Rev. Genet 9 267 -
Ekstrom , V.,Kumar , R.,Zhao , Y.,Yee , M.L.,Sung , C.,Toh , D.,Loh , P.Y.,Tan , J.,Teo , E. K.,Chow , W.C., 2016.Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourable IL28B polymorphism,Gastroenterol. Rep 5 208 -212
Feld , J.J.,Hoofnagle , J.H., 2005.Mechanism of action of interferon and ribavirin in treatment of hepatitis C,Nature 436 967 -
Ferenci , P.,Fried , M.W.,Shiffman , M.L.,Smith , C.I.,Marinos , G.,Gonçales , F.L.,Häussinger , D.,Diago , M.,Carosi , G.,Dhumeaux , D., 2005.Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin, 04 425 -433
Gale,Foy , E.M., 2005.Evasion of intracellular host defence by hepatitis C virus,Nature 436 939 -
Higgins , J.A.,Nasarabadi , S.,Karns , J.S.,Shelton , D.R.,Cooper , M.,Gbakima , A.,Koopman , R.P., 2003.A handheld real time thermal cycler for bacterial pathogen detection,Biosens 5663 00252 -1123
Hou , J., van Oord, G.,Groothuismink , Z.M.,Claassen , M.A.,Kreefft , K.,Zaaraoui-Boutahar,van Ijcken , W.F.,Osterhaus , A.D.,Janssen , H.L.,Andeweg , A.C., 2014.Gene expression profiling to predict and assess the consequences of therapyinduced virus eradication in chronic hepatitis C virus infection,J. Virol. 88 14 -12264
Idrees , M.,Riazuddin , S., 2008.Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission,BMC Infect. Dis. 8 1471 -
Jacobson , I.M., 2009.Treatment options for patients with chronic hepatitis C not responding to initial antiviral therapy,Clin. Gastroenterol 03 921 -930
Jehangir , K.,Khan , B.,Ayaz , A.,Muhammad , S.,Khalid , K., 2018.Hepatitis-C virus prevalence in district Shangla and evaluation of screening tests for anti-HCV, 50 1299 -1305
Khan , N.,Akmal , M.,Hayat , M.,Umar , M.,Ullah , A.,Ahmed , I.,Rahim , K.,Ali , S.,Bahadar , S.,Saleha , S., 2014.Geographic distribution of hepatitis C virus genotypes in pakistan,Hepatitis Monthly 14 -
Kim , W.R.,Flamm , S.L.,di Bisceglie , A.M.,Bodenheimer , H.C., 2008.Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease,Hepatology 47 1363 -1370
Klevens , R.M.,Hu , D.J.,Jiles , R.,Holmberg , S.D., 2012.Evolving epidemiology of hepatitis C virus in the United States,Clin. Infect. Dis. 55 S3 -S9
Malik , A.,-, 2016.-patients-in-Pakistan, -
Marinho , R.T.,Barreira , D.P., i40.Hepatitis C, stigma,World J. Gastroenterol. 19 6703 -
Messina , J.P.,Humphreys , I.,Flaxman , A.,Brown , A.,Cooke , G.S.,Pybus , O.G.,Barnes , E., 2015.Global distribution and prevalence of hepatitis C virus genotypes,Hepatology 61 77 -87
Ohno , O.,Mizokami , M.,Wu , R.R.,Saleh , M.G.,Ohba , K.I.,Orito , E.,Mukaide , M.,Williams , R.,Lau , J., 3b.New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a,J. clin. Microbiol 35 201 -207
Pearlman , B.L.,Traub , N., 2011.Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: A cure and so much more,Clin. Infect. Dis. 52 889 -900
Rosen , H.R., 2011.Chronic hepatitis C infection, 364 2429 -2438
Safi , S.,Badshah , Y.,Waheed , Y.,Fatima , K.,Tahir , S.,Shinwari , A.,Qadri , I., 2010.Distribution of hepatitis C virus genotypes, hepatic steatosis and their correlation with clinical and virological factors in Pakistan,-0032 4 253 -262
Shah , H.A.,Jafri , W.,Malik , I.,Prescott , L.,Simmonds , P.,Gastroenterol, 1997.Hepatitis C virus (HCV) genotypes and chronic liver disease in Pakistan, 12 1746 -761
Simmonds , P.,Bukh , J.,Combet , C.,Deléage , G.,Enomoto , N.,Feinstone , S.,Halfon , P.,Inchauspé , G.,Kuiken , C.,Maertens , G., 2005.Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes,Hepatology 42 962 -973
Stoddard , M.B.,Li , H.,Wang , S.,Saeed , M.,Andrus , L.,Ding , W.,Jiang , X.,Learn , G. H.,VonSchaewen,M. and Wen,J., 2015.molecular cloning, and analysis of full-length hepatitis C virus transmitted/founder genotypes 1, 3, and 4, 6 02518 -14
Stuyver , L.J.,Mcbrayer , T.R.,Whitaker , T.,Tharnish , P.M.,Ramesh , M.,Lostia , S.,Cartee , L.,Shi , J.,Hobbs , A.,Schinazi , R.F., 2004.Inhibition of the subgenomic hepatitis C virus replicon in huh7 cells by 2′-deoxy-2′-fluorocytidine, 48 651 -654
Ticehurst , J.R.,Hamzeh , F.M.,Thomas , D.L., 2007.Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis,J. clin. Microbiol 45 06 -2433
Tohme , R.A.,Holmberg , S.D., 2012.Transmission of hepatitis C virus infection through tattooing and piercing: a critical review,Clin. Infect. Dis. 54 1167 -1178
Veldt , B.J.,Heathcote , E.J.,Wedemeyer , H.,Reichen , J.,Hofmann , W.P.,Zeuzem , S.,Manns , M.P.,Hansen , B.E.,Schalm , S.W.,Janssen , H.L., 2007.Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis,Annls. Intern. Med 147 0003 -684
Waheed , Y.,Bhatti , A.,Ashraf , M., 2012.RNA dependent RNA polymerase of HCV: A potential target for the development of antiviral drugs,Infect. Genet 12 247 -257
Zhang , C.H.,Xu , G.L.,Jia , W.D.,Li , J.S.,J.L. and Ge,Y.S., 2011.Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: A meta-analysis of randomized controlled trials,Int. J. Cancer 129 1254 -1264
0

Citations

0

Downloads

77

Views